MP 601205

Drug Profile

MP 601205

Alternative Names: MP-601205; MPI-601,205

Latest Information Update: 16 Nov 2011

Price : $50

At a glance

  • Originator Mpex Pharmaceuticals
  • Class
  • Mechanism of Action Membrane protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Cystic fibrosis-associated respiratory tract infections

Most Recent Events

  • 30 Jun 2011 Rempex Pharmaceuticals acquires MP 601205 from Mpex Pharmaceuticals
  • 19 May 2008 Phase I development is ongoing
  • 01 Aug 2005 Mpex Pharmaceuticals has initiated a second phase Ib trial for Cystic fibrosis-associated respiratory tract infections in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top